首页> 美国卫生研究院文献>Translational Psychiatry >Review of withdrawal catatonia: what does this reveal about clozapine?
【2h】

Review of withdrawal catatonia: what does this reveal about clozapine?

机译:退出性卡塔尼亚评论:氯氮平有何启示?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Withdrawal symptoms are common upon discontinuation of psychiatric medications. Catatonia, a neuropsychiatric condition proposed to be associated with gamma-aminobutyric acid (GABA) hypoactivity due to its robust response to benzodiazepines, has been described as a withdrawal syndrome in case reports but is not a well-recognized phenomenon. The authors undertook a review of withdrawal catatonia with an aim to understand its presentation as well as the medications and psychoactive substances it is associated with. The review identified 55 cases of withdrawal catatonia, the majority of which occurred upon discontinuation of benzodiazepines (24 cases) and discontinuation of clozapine (20 cases). No other antipsychotic medications were identified as having been associated with the onset of a catatonic episode within 2 weeks following their discontinuation. Increasing GABA activity and resultant GABA receptor adaptations with prolonged use is postulated as a shared pharmacological mechanism between clozapine and benzodiazepines that underlie their association with withdrawal catatonia. The existing evidence for clozapine’s activity on the GABA system is reviewed. The clinical presentations of benzodiazepine withdrawal catatonia and clozapine withdrawal catatonia appear to differ and reasons for this are explored. One reason is that benzodiazepines act directly on GABAA receptors as allosteric agonists, while clozapine has more complex and indirect interactions, primarily through effects on receptors located on GABA interneurons. Another possible reason for the difference in clinical presentation is that clozapine withdrawal catatonia may also involve receptor adaptations in non-GABA receptors such as dopamine and acetylcholine. The findings from our review have implications for the treatment of withdrawal catatonia, and treatment recommendations are provided. Further research understanding the uniqueness of clozapine withdrawal catatonia among antipsychotic medication may give some insight as to clozapine’s differential mechanism of action.
机译:戒断症状在停用精神科药物时很常见。由于对苯二氮卓类药物的强烈反应,卡塔尼亚症是一种神经精神疾病,被认为与γ-氨基丁酸(GABA)机能减退有关,在病例报告中已被描述为戒断综合症,但尚未得到充分认识。作者对戒断卡塔顿进行了审查,目的是了解其症状以及与之相关的药物和精神活性物质。审查确定了55例卡塔尼亚性戒断,其中大多数发生在停用苯二氮类药物(24例)和停用氯氮平(20例)时。没有其他抗精神病药物被确认与中止发作后2周内发作有关。假定增加的GABA活性和长时间使用后产生的GABA受体适应性是氯氮平和苯并二氮杂类之间共同的药理机制,这是它们与戒断性卡塔顿关系的基础。审查了氯氮平在GABA系统上活性的现有证据。苯二氮卓戒断卡塔尼亚和氯氮平戒断卡塔尼亚的临床表现似乎有所不同,并对此进行了探讨。原因之一是苯二氮卓类药物作为变构激动剂直接作用于GABAA受体,而氯氮平具有更复杂和间接的相互作用,主要是通过对位于GABA中间神经元上的受体的作用。临床表现差异的另一个可能原因是氯氮平戒断卡塔尼亚也可能涉及非GABA受体(如多巴胺和乙酰胆碱)中的受体适应性。我们的审查结果对戒断性卡塔尼亚病的治疗有影响,并提供了治疗建议。进一步的研究了解抗精神病药物中氯氮平戒断卡塔尼亚的独特性,可能有助于了解氯氮平的不同作用机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号